Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 5/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.51 |
| ▸ | HRH2 | P25021 | 4/20 | 0.51 |
| ▸ | HRH1 | P35367 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096555 | 0.96 | MMP2 (0.67) | MMP2ALDH1A1MAPTMMP3RECQL | |
| SCHEMBL1618099 | 0.89 | ALDH1A1 (0.56) | MMP2ALDH1A1MAPTMMP3MMP1 | |
| SCHEMBL7561045 | 0.89 | PPARD (0.52) | MMP2ALDH1A1MAPTMMP3RECQL | |
| SCHEMBL9004244 | 0.89 | PPARD (0.52) | MMP2ALDH1A1MAPTMMP3RECQL | |
| SCHEMBL28563986 | 0.88 | APP (0.63) | MMP2ALDH1A1MAPTMMP3MMP1 | |
| SCHEMBL28563987 | 0.88 | APP (0.63) | MMP2ALDH1A1MAPTMMP3MMP1 | |
| SCHEMBL28566599 | 0.88 | APP (0.63) | MMP2ALDH1A1MAPTMMP3MMP1 | |
| SCHEMBL7590338 | 0.88 | MMP2 (0.63) | MMP2ALDH1A1MAPTMMP3MMP1 | |
| SCHEMBL6738645 | 0.88 | APP (0.63) | MMP2ALDH1A1MAPTMMP3MMP1 | |
| SCHEMBL7959136 | 0.88 | MAPT (0.54) | MMP2ALDH1A1MAPTMMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182382-A1 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | UNIV COPENHAGEN (DK) | 2024-06-06 | — | — | US | disclosed |
| EP-4305009-A2 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | University of Copenhagen (DK) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023085390-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2022189304-A2 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | UNIVERSITY OF COPENHAGEN (DK) | 2022-09-15 | — | — | WO | disclosed |
| EP-4056546-A1 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | University of Copenhagen (DK) | 2022-09-14 | — | — | EP | disclosed |
| CN-108440251-B | Method for photo/nickel concerted catalysis of monoarylation diol | 陕西师范大学 | 2021-01-01 | — | — | CN | disclosed |
| CN-107522673-B | 1,2,4, 5-tetrazine compound for bioorthogonal reaction and preparation method and application thereof | 北京师范大学 | 2020-05-19 | — | — | CN | disclosed |
| CN-110724026-A | In-situ deoxygenation fluorination synthesis method based on alcohol compound and 18F radioactive labeling method | 合肥工业大学 | 2020-01-24 | — | — | CN | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-6063885-A | Oxazoline or oxazine methacrylate aqueous coating compositions | S. C. JOHNSON COMMERCIAL MARKETS, INC. (US) | 2000-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182382-A1 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | NBAS, HRAS, NAA15 | MMP2 4418/4885ALDH1A1 747/4885MAPT 2572/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | MMP2 3993/4885ALDH1A1 510/4885MAPT 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.